Bigelovin is primarily studied for its potential anticancer properties. It has shown significant cytotoxic activity against various cancer cell lines, including those of the breast, lung, and liver, by inducing apoptosis and inhibiting cell proliferation. Research also indicates that bigelovin can suppress tumor growth by targeting specific signaling pathways such as NF-κB, which plays a key role in inflammation and cancer progression. Additionally, it exhibits anti-inflammatory effects, making it a candidate for development in both cancer therapy and inflammatory disease treatment. Due to its natural origin and potent bioactivity, bigelovin is of interest in pharmaceutical research for drug discovery and optimization of therapeutic agents.